Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: 5-fluorouracil
DRUG: Irinotecan
BIOLOGICAL: Bevacizumab
BIOLOGICAL: Cetuximab

Sponsor

Merck Sharp & Dohme LLC